Obesity is a complex disease and leading cause of morbidity and mortality and there are only insufficient treatment options available
New collaboration aims to develop novel peptide poly-agonists for the treatment of obesity and concomitant diseases
Gubra may receive up to EUR 240 million in upfront and success-based development and commercialization milestones plus staggered up to double-digit royalties on worldwide net sales
INGELHEIM, Germany & HØRSHOLM, Denmark -- (BUSINESS WIRE) --
Boehringer Ingelheim and Gubra announce a second collaboration and license agreement for the development of novel poly-agonist peptides to treat obesity. It will bring together Gubra’s established expertise in the design, synthesis, pharmaceutical characterization and in vivo testing of therapeutic peptides with Boehringer Ingelheim’s expertise in the research and development of innovative medicines in cardiometabolic diseases.
This second joint research and development program between Boehringer Ingelheim and Gubra builds on a successful ongoing collaboration in the obesity field, which was launched in 2017, and which has already achieved important milestones. It contributes to the growing Boehringer Ingelheim research and development stage portfolio in the obesity field.
“We look forward to expanding our productive collaboration with the Gubra team,” said Clive R. Wood, Ph.D., Corporate Senior Vice President Discovery Research at Boehringer Ingelheim. “I anticipate that these programs will help us bring much needed new treatment options for obesity patients.”
Boehringer Ingelheim has built a broad portfolio of marketed products for thromboembolic diseases, type 2 diabetes, acute stroke and myocardial infarction, hypertension and cardiovascular death risk reduction. With its extensive experience in the field and commitment to innovation, the company aims to transform the lives of people with cardiometabolic diseases.
Henrik Blou, CEO of Gubra said, “We are very pleased to enter into a second collaboration and license agreement with Boehringer Ingelheim focusing on the treatment of obesity. It is important for Gubra to find strong partners for our proprietary research programs, and our first collaboration with Boehringer Ingelheim has shown that the strengths of both companies are nicely complementary. Joining forces on this novel research program has the potential to take obesity treatment to the next level to the benefit of patients around the world.”
Rimini Street荣获多项客户销售与服务世界奖
聚豪情商务联盟携手天赐良田,玖夫牌富硒大米
Vifor Pharma and Angion
Spesolimab meets primary
Aeternals:新型NFT和互动技术相结合
Boehringer Ingelheim Launches
DCAS开始接受2024年非经销商委员会会员申请
Carestream Health将其医疗保健IT业务
Kymeta 宣布其下一代天线、终端和全球移动连接
电池生产商Hithium将为储能系统开发商Perfect
Mythical Games完成3700万美元C1轮融资
苏爱康医药宣布在日本推出Darvias®
面对疫情和经济危机,亿康先达发布强劲的20
IDEMIA和Resa Airport Data Syst
回顾激情燃烧的建设岁月 传承兰西拉艰苦奋斗
Sabre选择DXC Technology来助力改变未
广成明股份参加番禺区先进制造业强区座谈会
Mavenir的虚拟无线接入网(vRAN)连续第二年在
森永乳业的益生菌长双歧杆菌BB536在其50周年庆
Intelsat向史密森国家航空航天博物馆捐赠
全球投资者法律顾问ROSEN鼓励Athira Pharma
深圳三匹马出行科技与江铃集团新能源战略合作
在大地上书写责任与担当——渭南师范学院孙樵
村田首款面向Wi-Fi 6E/7的寄生元件耦合器实现商